Antiplatelet drugs help in preventing blood clots which can reduce the risk of heart attacks and strokes. They are widely used for patients receiving coronary artery stents and those with conditions like coronary artery disease or peripheral vascular disease. The increasing burden of cardiovascular diseases is driving the demand for antiplatelet drugs globally.
The global Antiplatelet Drugs Market is estimated to be valued at US$ 2674.22 Bn in 2024 and is expected to exhibit a CAGR of 12% over the forecast period 2024 to 2031, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
The adoption of combination antiplatelet therapy has increased significantly over the past few years. Combination of antiplatelet drugs having different mechanisms of action helps provide better protection against arterial thrombosis without significantly increasing the risk of bleeding. Drugs like aspirin and clopidogrel are commonly used in combination. The approval and launch of newer oral antiplatelet drugs with improved efficacy and safety profiles is also influencing the adoption of combination antiplatelet therapy. This shift is expected to drive the demand for antiplatelet drugs during the forecast period.
Segment Analysis
The global antiplatelet drugs market is dominated by the aspirin sub segment. Aspirin is considered as the gold standard antiplatelet drug for most of the indications due to its effectiveness and low cost. It is used for prevention of cardiovascular diseases, thromboembolic stroke and myocardial infarction. Aspirin is widely used drug for prevention of artery-clogging blood clots thus prevents heart attacks, strokes and other cardiovascular problems.
Key Takeaways
The global antiplatelet drugs market analysis is expected to witness high growth over the forecast period of 2024 to 2031. The global Antiplatelet Drugs Market is estimated to be valued at US$ 2674.22 Bn in 2024 and is expected to exhibit a CAGR of 12% over the forecast period 2024 to 2031.
Regional analysis - Asia Pacific region currently dominates the global antiplatelet drugs market and is estimated to be the fastest growing region during the forecast period. High population, increasing awareness about cardiovascular diseases and growing healthcare expenditures are some factors driving the growth of antiplatelet drugs market in Asia Pacific region.
Key players related content comprises - Key players operating in the antiplatelet drugs market are Chang Chun Group, Covestro AG, Dow, and Hexio. Chang Chun Group is a leading manufacturer of aspirin and clopidogrel tablets globally. Covestro AG provides specialty chemicals for manufacturing of clopidogrel. Dow offers antiplatelet drug excipients to various pharmaceutical companies. Hexio has strong presence in Asia Pacific antiplatelet drugs market through its aspirin and clopidogrel generics.
Get more insights on this topic: https://www.newswirestats.com/antiplatelet-drugs-market-industry-insights-trends-antiplatelet-drugs-market/
Comments
0 comment